Plain-English translation of NCT07011043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called , which is a type of antibody designed to target and reduce certain immune cells that cause lupus. The study will give patients a single intravenous infusion (injection into a vein) and then monitor how safe the treatment is, how their body processes it, and whether it helps reduce lupus symptoms.
Many lupus patients don't improve enough with current standard treatments. This trial is exploring whether this new medication, which works differently by targeting a specific type of immune cell, might offer another option for people whose lupus isn't adequately controlled.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of the medication at one visit. After that, the research team will monitor you over time with blood tests and check-ins to see how your body responds to the treatment, measure how the medication moves through your system, and track whether your lupus improves. The study will test four different dose levels, with each group of patients receiving a different amount to find the safest and most effective dose.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Bulgaria
Georgia